Skip to content
OpenCapital
Get started

Apimeds Pharmaceuticals US, Inc. APUS Q1 2026 Annual earnings

Reported May 26, 2026 · Before market open

Diluted EPS-$2.26

Next report

Date not yet announced

Versus estimates

Diluted EPS

Q1 2026-$2.26
Q3 2025-$0.14Q2 2025-$0.26Q1 2025-$0.05Q4 2024-$0.02Q3 2024-$0.03

Ask the moment Apimeds Pharmaceuticals US, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Apimeds Pharmaceuticals US, Inc. report Q1 2026 earnings?
Apimeds Pharmaceuticals US, Inc. (APUS) reported Q1 2026 earnings on May 26, 2026 before market open.
What were Apimeds Pharmaceuticals US, Inc.'s Q1 2026 revenue and EPS?
Apimeds Pharmaceuticals US, Inc. reported diluted EPS of $-2.26 for Q1 2026.
How did Apimeds Pharmaceuticals US, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 4420.0% from $-0.05.
Where can I find Apimeds Pharmaceuticals US, Inc.'s Q1 2026 SEC filings?
You can read the 10-K periodic report (0001213900-26-051139) directly on SEC EDGAR. The filing index links above go to sec.gov.